These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19894348)

  • 1. [Molecular-targeted therapy in the developing stage. 1) VEGFR-TKI and EGFR-TKI].
    Yano S
    Nihon Naika Gakkai Zasshi; 2009 Aug; 98(8):1887-93. PubMed ID: 19894348
    [No Abstract]   [Full Text] [Related]  

  • 2. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

  • 3. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
    Kim YH; Mio T; Mishima M
    Intern Med; 2009; 48(18):1677-9. PubMed ID: 19755773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.
    Zhong H; Bowen JP
    Curr Top Med Chem; 2011; 11(12):1571-90. PubMed ID: 21510831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hair growth after gefitinib treatment.
    Lee LW; Burt PA
    Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):492-3. PubMed ID: 16149296
    [No Abstract]   [Full Text] [Related]  

  • 6. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
    Vidal ÓJ
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
    Song T; Yu W; Wu SX
    Asian Pac J Cancer Prev; 2014; 15(1):205-13. PubMed ID: 24528028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular targeted therapies and cytotoxics: Friends or foes?].
    Vignot S; Zalcman G
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S91-2. PubMed ID: 26118883
    [No Abstract]   [Full Text] [Related]  

  • 12. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor].
    Kakiuchi S; Yano S; Sone S
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1831-8. PubMed ID: 16223143
    [No Abstract]   [Full Text] [Related]  

  • 14. Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases.
    Ishida A; Kanoh K; Nishisaka T; Miyazu Y; Iwamoto Y; Kohno N; Miyazawa T
    Intern Med; 2004 Aug; 43(8):718-20. PubMed ID: 15468973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer.
    Bonomi PD
    Am J Health Syst Pharm; 2003 Dec; 60(24 Suppl 9):S16-21. PubMed ID: 14717024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
    Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.
    Tanaka K; Hata A; Kida Y; Kaji R; Fujita S; Katakami N; Imai Y
    Intern Med; 2012; 51(6):659-61. PubMed ID: 22449680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An appraisal of anticancer activity with structure-activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review.
    Haider K; Das S; Joseph A; Yar MS
    Drug Dev Res; 2022 Jun; 83(4):859-890. PubMed ID: 35297084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
    Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.